Darmstadt, Germany

Fabian-Pascal Schmied

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Evonik Operations Gmbh. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fabian-Pascal Schmied: Innovator in Methacrylic Copolymers

Introduction

Fabian-Pascal Schmied is a notable inventor based in Darmstadt, Germany. He has made significant contributions to the field of polymer chemistry, particularly through his innovative work on methacrylic copolymers. His research has implications in various applications, including pharmaceuticals and nutraceuticals.

Latest Patents

Schmied holds a patent for a novel methacrylic copolymer that contains units derived from at least one alkyl methacrylate and methacrylamide. This unique copolymer features methacrylamide units that constitute at least 34 wt.-% of the total weight. The patent outlines a method for preparing these copolymers, which can be utilized in pharmaceutical compositions, nutraceutical compositions, and coated dosage forms. Additionally, the methacrylic copolymer serves as a coating, carrier, and matrix for amorphous solid dispersions.

Career Highlights

Fabian-Pascal Schmied is currently employed at Evonik Operations GmbH, where he continues to advance his research in polymer science. His work has garnered attention for its potential to enhance drug delivery systems and improve the efficacy of various formulations.

Collaborations

Schmied collaborates with esteemed colleagues, including Thomas Endres and Christian Moers. These partnerships contribute to the innovative environment at Evonik Operations GmbH, fostering advancements in polymer technology.

Conclusion

Fabian-Pascal Schmied is a prominent figure in the field of methacrylic copolymers, with a patent that showcases his innovative approach to polymer chemistry. His contributions have the potential to significantly impact the pharmaceutical and nutraceutical industries.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…